Search results
- New Delhi: Zydus Lifesciences on Friday said it has tied up with Lucknow-based CSIR-Central Drug Research Institute (CDRI) to develop a drug for chronic kidney disease-induced osteoporosis.
pharma.economictimes.indiatimes.com/news/mergers-and-acquisitions/zydus-ties-up-with-csir-cdri-to-develop-drug-for-ckd-induced-osteoporosis/113759973Novel Drugs India: Zydus ties up with CSIR-CDRI to develop ...
People also ask
Is Zydus partnering with CSIR to develop a drug for osteoporosis?
Will Zydus develop a drug for chronic kidney disease-induced osteoporosis?
Is Zydus a synergy with CSIR-CDRI?
4 days ago · New Delhi: Zydus Lifesciences on Friday said it has tied up with Lucknow-based CSIR-Central Drug Research Institute (CDRI) to develop a drug for chronic kidney disease-induced osteoporosis. A collaborative research agreement was inked between the parties to develop oral medication through the discovery of small molecule inhibitors of Sclerostin, the Ahmedabad-based drug firm said in a regulatory filing.
- Zydus ties up with CSIR-CDRI to develop drug for CKD-induced ...
New Delhi: Zydus Lifesciences on Friday said it has tied up...
- CDRI Unveils Protein-Drug Combination to Combat Osteoporosis ...
After five years of research, CDRI discovers a promising...
- Zydus ties up with CSIR-CDRI to develop drug for CKD-induced ...
4 days ago · New Delhi: Zydus Lifesciences on Friday said it has tied up with Lucknow-based CSIR-Central Drug Research Institute (CDRI) to develop a drug for chronic kidney disease-induced osteoporosis. As per ...
2 days ago · Unfortunately, most of the conventional anti-osteoporosis medications are contraindicated in patients with CKD, due to the risk of worsening renal function. Therefore, there is an urgent need to develop safe and effective drugs for osteoporosis that will reduce fracture risk without a deterioration of renal function.
1 day ago · Based on research conducted at CDRI and data from antibody-based therapies (biologics), Sclerostin has emerged as a promising drug target for treating CKD-induced osteoporosis as well as postmenopausal osteoporosis. Pankaj Patel, Chairman, Zydus Lifesciences Limited, on this occasion said, “Zydus has a significant focus on chronic kidney ...
2 days ago · After five years of research, CDRI discovers a promising protein-drug combo targeting osteoporosis induced by chronic kidney disease, partnering with Zydus Lifesciences to improve patient care.
CSIR-CDRI's deep-rooted expertise in biomedical research, coupled with Zydus's innovative approach to drug discovery and development, creates a powerful synergy. Together, we'll explore new avenues for treating bone metabolism disorders, ensuring that CKD patients have access to effective and affordable therapies that improve their quality of ...
5 days ago · Zydus Lifesciences on Friday said it has tied up with Lucknow-based CSIR-Central Drug Research Institute (CDRI) to develop a drug for chronic kidney disease-induced osteoporosis. A collaborative research agreement was inked between the parties to develop oral medication through the discovery of small molecule inhibitors of Sclerostin, the ...
